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Abstract
Background: Radioiodine represents a cost-effective treatment option for Graves’ disease. In the UK, it is
traditionally reserved for patients who relapse after initial thionamide therapy. In a change from current practice,
the new guidelines of the National Institute for Health and Care Excellence (NICE) recommends that radioiodine
should now be first line therapy for Graves’ disease. However, the safety of radioiodine with respect to long-term
mortality risk has been the subject of recent debate. This analysis examines evidence from treatment related
mortality studies in hyperthyroidism and discusses their implications for future Graves’ disease treatment strategies.
Main body: Some studies have suggested an excess mortality in radioiodine treated cohorts compared to the
background population. In particular, a recent observational study reported a modest increase in cancer-related
mortality in hyperthyroid patients exposed to radioiodine. The interpretation of these studies is however
constrained by study designs that lacked thionamide control groups or information on thyroid status and so could
not distinguish the effect of treatment from disease. Two studies have shown survival advantages of radioiodine
over thionamide therapy, but these benefits were only seen when radioiodine was successful in controlling
hyperthyroidism. Notably, increased mortality was associated with uncontrolled hyperthyroidism irrespective of
therapy modality.
Conclusions: Early radioiodine treatment will potentially reduce mortality and should be offered to patients with
severe disease. However, thionamides are still suitable for patients with milder disease, contraindications to
radioiodine, or individuals who choose to avoid permanent hypothyroidism. Ultimately, a patient individualised
approach that prioritises early and sustained control of hyperthyroidism will improve long-term outcomes
regardless of the therapy modality used.
Keywords: Graves’ disease, Hyperthyroidism, Radioiodine therapy, Thyroidectomy, Mortality, Major adverse
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Background
The choice of primary therapy in Graves’ disease is one
of the more contentious issues in clinical thyroidology.
Three well established therapies, namely antithyroid
drugs, radioiodine, and thyroidectomy have been avail-
able for decades, and their efficacy and limitations are
well recognised (Table 1) [1, 2]. Thionamide drugs offer
the prospect of remission without the need for lifelong
thyroid hormone replacement but only about 45% of pa-
tients achieve long-term remission [3]. Ablative treat-
ment with radioiodine or thyroidectomy result in better
cure rates and overcome the risk of non-compliance
with thionamides, but both treatments incur the need
for permanent levothyroxine therapy [1, 2]. Thyroidec-
tomy also carries risks of permanent hypoparathyroidism
and laryngeal nerve damage while radioiodine may ag-
gravate orbitopathy and entails exposure to radioiso-
topes which is unsuitable for young children, pregnant
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women, or patients planning pregnancy [1, 2]. In prac-
tical terms radioiodine has the added advantage that it is
administered in a single outpatient visit without the risks
and overheads of surgery.
Radioiodine is the preferred therapy in the United
States whereas in Europe and most of Asia, it is reserved
as second line for patients who relapse after initial thio-
namide treatment [4]. The recent guidelines of the UK
National Institute for Health and Care Excellence
(NICE) recommends that radioiodine should now be
first line treatment for Graves’ disease in the UK
(Table 2) [5]. This position represents a departure from
current practice and is largely based on the superior
cost-effectiveness and efficacy of radioiodine compared
to thionamides [6]. The importance of treatment efficacy
has also been highlighted by a number of recent obser-
vational studies that have shown an increase in long-
term cardiovascular mortality in poorly controlled pa-
tients with hyperthyroidism [7–10]. However, a recent
large-scale study in patients with hyperthyroidism re-
ported increased cancer mortality in association with
radioiodine treatment [11]. This study has raised con-
cern regarding the safety of radioiodine and hence the
implications of the NICE guidance. A critical appraisal
of these and other treatment-related mortality studies in
hyperthyroidism is therefore necessary to ascertain the
safety of the proposed NICE approach.
Main text
Although the association between hyperthyroidism and
adverse cardiovascular outcomes is well-recognised, only
a handful of studies have specifically addressed the long-
term consequences of treatment on mortality. Such out-
comes are particularly relevant to Graves’ disease pa-
tients since they are relatively young and are expected to
enjoy a lengthy survival in the aftermath of treatment.
Furthermore, unlike patients with toxic nodules who re-
quire ablative treatment, Graves’ disease can be cured by
all three treatments, making it essential to understand
the lasting effects of treatment. There are no randomised
controlled trials on long-term mortality outcomes in
Graves’ disease and our understanding of treatment-
related survival is based on data from observational
studies conducted in a variety of settings and methodo-
logical designs. Our focus in this analysis is on studies
that have evaluated total, cardiovascular, or cancer re-
lated mortality in radioiodine treated cohorts, either in
comparison with the background population (Table 3)
or with other treatment modalities (Table 4).
Radioiodine vs population controls
Studies from the United States [12], Sweden [13], UK
[15], and Finland [18] all reported increased all-cause
mortality compared to the background general popula-
tion in patients who received radioiodine therapy for
hyperthyroidism (Table 3). In these studies, excess
Table 1 Pros and cons of Graves’ disease treatments
Antithyroid drugs Radioiodine Thyroidectomy
Pros • Prospect of euthyroid remission
• Permanent hypothyroidism - rare
• Used in pregnancy
• Non-invasive
• Rapid control (weeks)
• Cure rates ~ 80–90%
• Single outpatient treatment
• Side-effects minor and rare
• Cost-effective
• Rapid control (days)
• Cure rates ~ 100% for total thyroidectomy
• Useful in patients with co-existent primary
hyperparathyroidism, malignancy, large goitres
or airway compression
Cons • Low remission rates ~ 45%
• Risk of relapse in future pregnancy or postpartum
period
• 12–18 months of treatment required
• Major drug side effects: agranulocytosis, liver
toxicity, cholestatic liver disease, ANCA positive
vasculitis, acute pancreatitis
• Risk of birth defects if used in first trimester of
pregnancy
• Aggravation of orbitopathy
• Permanent hypothyroidism
• Radiation restrictions after
treatment
• Contraindicated in pregnancy due
to risks of fetal anomalies and fetal
hypothyroidism
• Contraindicated in individuals
imminently planning pregnancy
• Need to wait 6 months after
treatment before conception or
fathering a child
• Anaesthetic risks
• Risk of permanent hypoparathyroidism
• Risk of recurrent laryngeal nerve damage
• Permanent hypothyroidism
• Neck scar
• Best avoided in pregnancy due to surgical and
anaesthetic risks on fetus and mother
Table 2 NICE guidelines on first line treatment for Graves’
disease in adults [5]
1.6.10
Offer radioactive iodine as first-line definitive treatment for adults with
Graves’ disease, unless antithyroid drugs are likely to achieve remission
(see recommendation 1.6.11), or it is unsuitable (for example, there are
concerns about compression, malignancy is suspected, they are preg-
nant or trying to become pregnant or father a child within the next 4 to
6 months, or they have active thyroid eye disease).
1.6.11
Offer a choice of antithyroid drugs (a 12 to 18-month course) or radioac-
tiveiodine as first-line definitive treatment for adults with Graves’ disease
if antithyroid drugs are likely to achieve remission (for example, mild
and uncomplicated Graves’ disease).
1.6.12
Offer antithyroid drugs (a 12 to 18month course) as first-line definitive
treatment for adults with Graves’ disease if radioactive iodine and
surgery are unsuitable.
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deaths were attributable to cardiovascular disorders, and
in some cases, mortality increased with higher radioio-
dine doses [15]. A more varied picture is seen with can-
cer mortality, with reports of increased [11, 14, 18],
similar [12] or even decreased [16], overall cancer mor-
tality risk in radioiodine-treated patients with hyperthy-
roidism. In positive studies, increased cancer risk was
dose dependent [11, 14, 18] and attributable to upper
gastroesophageal [14, 18], respiratory tract [14] or breast
tumours [11] suggesting that the malignancies were a
consequence of internal exposure to radioactivity in iod-
ide accumulating organs. Cancer mortality risk was also
increased in younger versus older patients and in pa-
tients with toxic nodules compared to Graves’ disease
Table 3 Mortality studies in hyperthyroidism: treatment groups vs disease-free/population controls
Author (ref) Year Country Setting No of patients Total/CV mortality RR (95%CI) Cancer mortality RR (95%CI)
Radioactive Iodine vs disease-free/population controls
Goldman [12] (a) 1988 USA Hospital 1762 Increased; SMR 1.3 (1.2, 1.4) No difference; SMR 0.9 (0.7, 1.1)
Goldman [12] (b) 1988 USA Hospital 607 Increased; SMR 1.2 (1.1, 1.4) No difference; SMR 1.0 (0.7, 1.3)
Hall [13, 14] 1992, 1993 Sweden Hospital 10,552 Increased; SMR 1.5 (1.4, 1.5) Increased; SMR 1.1 (1.0, 1.2)
Franklyn [15, 16] 1998, 1999 UK Register 7209, 7417 (c) Increased; SMR 1.1 (1.1, 1.2) Decreased; SMR 0.9 (0.8, 0.9)
Ron [17] 1998 USA/UK CTTFUS 35,593 NA No difference; SMR 1.0 (0.9, 1.0)
Metso [18] 2007 Finland Hospital 2793 Increased; SMR 1.1 (1.0, 1.2) Increased; RR 1.3 (1.1, 1.6)
Kitahara [11] 2019 USA/UK CTTFUS 18,805 NA Increased; RR 1.1 (1.0, 1.1)
Antithyroid Drugs vs disease-free/population controls
Ron [17] 1998 USA/UK CTTFUS 35,593 NA Increased; SMR 1.3 (1.1, 1.6)
Boelaert [7] 2013 UK Hospital 1036 (d) Increased; SMR 1.3 (1.1, 1.6) (d) No difference; SMR 1.0 (0.7, 1.6)
Okosieme [8] 2019 UK Registry 3587 Increased; RR 1.2 (1.0, 1.5) NA
Thyroidectomy vs disease-free/population controls
Ryodi [19] 2013 Finland Registry 4334 No difference; RR 0.91, (0.8, 1.1) (e) NA
RR relative risks, CI confidence interval, CV cardiovascular, CTTFUS Cooperative Thyrotoxicosis Therapy Follow-up study cohort, SMR Standardised Mortality Ratio,
NA Not assessed
(a), 80% of cohort treated with RAI, (b), Radioiodine treated cohort only, (c) Numbers are for the 1998 and 1999 cohorts respectively, (d) For reference [7] HR are
based on person years accumulated during thionamide therapy in 1036 patients of which 272 received antithyroid drugs alone and 764 received radioiodine with
or without antithyroid drugs, (e) RR for CV mortality
Table 4 Mortality studies in hyperthyroidism: treatment groups vs disease controls
Author (ref) Year Country Setting No of patients Total/CV mortality RR (95%CI) Cancer mortality RR (95%CI)
RAI vs Thyroidectomy
Hoffman [20] 1982 USA Hospital 1005 vs 2141 (RAI vs T) No difference; RR 1.0 (0.9, 1.2) No difference; RR 1.0 (0.7, 1.3) (a)
Ryodi [21, 22] 2015,
2018
Finland Registry 1814 vs 4334 (RAI vs T) Increased; HR 2.1 (1.7, 2.5) (b) No difference; RR 1.0 (0.9, 1.2)
Giesecke [23] 2017 Sweden Registry 10,250 vs 742 (RAI vs T) Increased; HR 1.2 (1.0,1.4) No difference; HR 0.96 (0.73, 1.3)
RA1 vs ATD
Boelaert [7] 2013 UK Hospital 764 vs 272 (RAI-Grp A vs ATD)
(7a)
Reduced; HR 0.7 (0.5, 0.9) NA
764 vs 272 (RAI-Grp B vs ATD)
(7b)
No difference; HR 0.9 (0.7, 1.3) NA
Okosieme [8] 2019 UK Registry 250 vs 3587 (RAI-Grp A vs ATD)
(8a)
Reduced; HR 0·5 (0·3, 0.9) NA
182 vs 3587 (RAI-Grp B vs ATD)
(8b)
No difference; HR 1·5, (0·9, 2·4) NA
Gronich [24] 2020 UK Database 2829 vs 13,808 (RAI vs ATD) Reduced; HR 0.83 (0.72, 0.95) No difference; HR 1.0 (0.8, 1.2) (a)
RR relative risks, CI confidence interval, CV cardiovascular, RAI Radioactive Iodine, T Thyroidectomy, ATD Antithyroid Drugs, SMR Standardised Mortality Ratio
(a), RR/HR for cancer incidence, (b), HR for CV mortality. (7a, 7b) For reference [7], HR are based on person years accumulated after RAI and on Levothyroxine
(RAI-Grp A) or person years after RAI but not taking or before taking Levothyroxine (RAI-Grp B) vs person years on thionamide alone (ATD). (8a, 8b) For reference
[8], radioiodine groups were divided into patients with resolved hyperthyroidism after radioiodine (RAI-Grp A) and patients with unresolved hyperthyroidism after
radioiodine (RAI-Grp B)
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patients [14]. Clearly a key limitation of these studies is
the absence of hyperthyroid control groups that were
not exposed to radioiodine thus making it difficult to
distinguish the effects of radioiodine from those of
hyperthyroidism per se. For the same reason, cumulative
dose related risks cannot simply be ascribed to a radio-
iodine effect since patients with more severe disease would
have received higher or multiple doses of radioiodine.
Of interest is the recent study by Kitahara et al which
evaluated cancer mortality in 18,805 radioiodine-treated
patients from the Cooperative Thyrotoxicosis Therapy
Follow-up study cohort (CTTFUS) [11]. The CTTFUS is
a long-running longitudinal cohort of more than 35,000
hyperthyroid patients enrolled between 1946 and 1964
in the United States and United Kingdom. Using a novel
dosimetric model to estimate the tissue radioiodine dose,
the authors showed a modest association between radio-
iodine treatment and solid cancer deaths (Relative Risk
[RR] 1.06, 95% Confidence Interval [CI], 1.02–1.10).
However, the study faces the same challenges in inter-
pretation as other radioiodine cohort studies that lacked
hyperthyroid control groups. In addition, the dosimetric
model used in the study was based on a series of as-
sumptions which resulted in uncertainties in the tissue
dose estimates. Also, the study did not adjust for rele-
vant confounders for cancer risk including smoking,
obesity, alcohol intake, and thyroid status [11]. Lastly,
the association with breast or solid cancer risk seems
implausible given that the mean radioiodine dose in the
study was < 500MBq which is about a tenth of the usual
treatment doses administered to thyroid cancer patients
[25]. Solid tumours are not seen in association with the
higher doses used in thyroid cancer treatment and only
a small risk of leukaemia has been reported in thyroid
cancer patients [25].
In an unusual development, two of the study co-
authors have published a critique of their own study
along with additional analysis from the same dataset but
with the inclusion of hyperthyroid groups unexposed to
radioiodine [26]. Using conventional standardised mor-
tality ratios (SMR), this supplementary analysis showed
no excess cancer mortality in radioiodine-treated pa-
tients but in contrast observed an increased cancer mor-
tality in patients treated exclusively with antithyroid
drugs (SMR 1.28, 95% CI 1.09–1.48) [26]. This mortality
was due to deaths from cancers of the buccal cavity,
digestive tract, and all solid cancers and are consistent
with a previous analysis of the CTTFUS cohort by Ron
et al which also used SMRs to show excess cancer deaths
in thionamide treated but not in radioiodine-treated
patients [17]. More recently, Gronich et al examined
cancer risk in 16,637 hyperthyroid patients sourced from
a health care database. Correcting for age, sex, smoking
history and body mass index amongst other variables the
authors found no association between radioiodine
therapy and total or individual cancer risk in long-term
follow up [24]. The reasons for these discrepancies are
unclear and may reflect differences in analytical methods
but nonetheless call for further clarification.
Radioiodine vs thyroidectomy
A second approach has been to compare mortality
outcomes in radioiodine versus thyroidectomy cohorts
(Table 4). A 1982 Mayo clinic study showed no difference
in total or cancer related mortality in radioiodine versus
surgically treated women with hyperthyroidism [20]. Two
recent national registry studies from Finland and Sweden
have shown an increase in all-cause mortality [23] and
cardiovascular mortality [21] in radioiodine treated pa-
tients compared to thyroidectomy patients. In contrast
differences in cancer related mortality were not observed
between the two groups in these cohorts [22, 23]. Again,
these studies did not include thionamide only groups and
did not account for the severity and duration of hyper-
thyroidism exposure before and after definitive treatment.
In the Finnish study, excess cardiovascular morbidity was
not seen in radioiodine treated patients who developed
hypothyroidism or in surgically treated patients compared
to the background population [19], suggesting that the
survival advantages of surgery over radioiodine therapy
may be related to the superior hyperthyroidism control
achieved with thyroidectomy [21].
Radioiodine versus thionamide
Three studies compared mortality in radioiodine versus
thionamide treated patients (Tables 3 and 4). The first is
the CTTFUS study by Ron et al which showed excess
cancer deaths in thionamide but not radioiodine-treated
patients [17]. A 2013 hospital clinic study by Boelaert
et al comprising 1036 hyperthyroid patients compared
mortality according to thionamide or radioiodine treat-
ment [7]. Using a time-dependent regression model, they
showed reduced mortality in association with radioio-
dine but only after it led to hypothyroidism, implying
survival advantages of hyperthyroidism control. In a
recent record linkage study in South Wales, UK, we eva-
luated cardiovascular morbidity and mortality according
to the modality and effectiveness of primary therapy in
Graves’ disease (n = 4189) [8]. We used a one-year land-
mark analytical approach to show that early and success-
ful radioiodine treatment was associated with a 50%
reduction in mortality compared to thionamide treat-
ment but this survival advantage was lost when radioio-
dine failed to control hyperthyroidism by the one-year
landmark. In addition the free T4 concentration after
initial treatment was positively associated with long-
term mortality and persistent hyperthyroidism carried a
Okosieme et al. Thyroid Research            (2020) 13:3 Page 4 of 7
55% increase in mortality risk independent of therapy
modality [8].
Two recent Danish registry studies have also shown
associations between cumulative hyperthyroidism expos-
ure and mortality or cardiovascular events in patients
with hyperthyroidism although treatment modality was
not evaluated in these studies [9, 10]. The above findings
support the well-established detrimental effects of thy-
roid hormone excess on the cardiovascular system, and
this may explain some of the inconsistencies in previous
data. In the study by Ron et al, increased cancer mortal-
ity in patients treated with antithyroid drugs can be ex-
plained by less effective thyroid control in thionamide
treated patients rather than a carcinogenic effect of thio-
namides per se [17]. A similar mechanism may be at
play for the superior outcomes observed for thyroidec-
tomy compared to radioiodine [21–23] as well as the
survival advantages of achieving a hypothyroid state in
the aftermath of radioiodine therapy [21].
Individualised treatment
Thus, in patients with hyperthyroidism, the risk of mor-
tality, whether cardiocvascular or cancer mortality, ap-
pears to be driven by thyroid hormone excess above all.
Even if there was a marginal risk of radioiodine related
cancer, such risk would clearly be offset by the overall
survival gains seen with disease control after radioiodine.
The prospect of improving survival with better treat-
ment has led some experts to suggest a ‘patient-tailored’
treatment approach to Graves’ disease management [27].
This strategy would offer early definitive therapy to pa-
tients with unfavourable characteristics such as severe
disease, large goitres, or high TRAb levels, while thiona-
mides are reserved for less severe cases. In this regard
the current NICE guidelines are a step in the right direc-
tion and should enable more efficient individualised care
(Table 2). However, the guidance risks being interpreted
as an endorsement of radioiodine over other therapies
whereas the reality is more nuanced. In particular the
issue of therapy choice must not overshadow the central
importance of controlling hyperthyroidism which is
feasible with any therapy modality. In our study 39% of
patients remained hyperthyroid one-year after diagnosis
with an increased risk of subsequent death [8] under-
pinning the need for prompt control of hyperthyroidism
as a core standard of care.
Thionamides are increasingly used as first line therapy
for Graves’ disease globally, even in the United States
where radioiodine has traditionally been preferred [4].
The extent to which this will change in the UK with the
advent of NICE is uncertain since radioiodine would re-
main unsuitable for a sizable proportion of the Graves’
disease population including patients with orbitopathy,
pregnant women, individuals intending pregnancy [28],
or patients with young children. Some patients may pre-
fer thionamides due to concerns with permanent
hypothyroidism, weight gain, or reduced quality of life
on levothyroxine. Such concerns are not unfounded. A
study of Swedish Graves’ disease patients randomised to
treatment with thionamides, radioiodine, or surgery,
showed no difference in treatment satisfaction [29] or
long-term quality of life between the treatment arms
[30]. However, a more recent study, also from Sweden,
in which Graves’ disease patients were followed up for
6–10 years after primary therapy, showed that the pro-
portion of patients who felt fully recovered was signifi-
cantly lower amongst those receiving levothyroxine
compared to those not on levothyroxine [3].
In addition, some studies have suggested that weight
gain after treatment of hyperthyroidism may be more
pronounced with ablative therapy than antithyroid drug
therapy [31]. A retrospective study in 133 hyperthyroid
patients reported more weight gain in patients rendered
hypothyroid with radioiodine or total thyroidectomy
compared to those who remained euthyroid after thiona-
mides or hemithyroidectomy [31]. In another study of
162 hyperthyroid patients an average weight gain of 5 kg
and BMI increase of 8 kg/m2 was documented over a
mean period of 24 months. Weight gain was similar for
patients who received antithyroid drugs or radioiodine
treatment but was significantly greater for patients who
had been treated with thyroidectomy (5 kg vs 10 kg;
P = 0.007). Overall, weight gain was associated with
development of hypothyroidism despite levothyroxine
replacement [32]. Thus, individuals who opt for
thionamides should be reassured that their choices
are valid and that optimal outcomes can still be
achieved provided hyperthyroidism is controlled as
early as possible.
Also relevant to treatment decisions are the resource
and health economic implications of treatment. Thus,
centres who do not have easy access to nuclear medicine
facilities or lack the expertise of experienced high-
volume thyroid surgeons may lean towards the use of
antithyroid drugs over more definitive therapies. Such
an approach is not unreasonable and centres should be
equipped with robust protocols to use antithyroid drugs
at doses and treatment durations that promote early and
lasting resolution of hyperthyroidism. A cost-utility ana-
lysis by Donovan et al on the lifetime cost-effectiveness
of the three first-line therapies in Graves’ disease in
England and Australia, showed that radioiodine was
more cost effective than antithyroid drugs or surgery but
that antithyroid drugs still offered a cost-effective alter-
native to radioiodine [6]. However, these results were
highly sensitive to the quality of life weights attached to
post-ablative hypothyroidism and euthyroidism on
antithyroid drug therapy.
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Conclusions
The controversy surrounding Graves’ disease manage-
ment is likely to continue, but the emphasis must now
move away from binary positions on treatment modality
and seek pragmatic strategies to optimise the safety, effi-
ciency, and outcomes of existing therapies. Regardless of
therapy modality, a treatment approach that prioritises
early control of hyperthyroidism will ultimately improve
long-term outcomes. The challenge for clinicians will be
to identify which patients will respond to thionamides
and can be spared ablation and lifelong levothyroxine. A
number of useful clinical scores for predicting thiona-
mide response are in use [33, 34], but these scores will
require further refinement and validation. Although
randomised controlled trials with long-term mortality
endpoints are now increasingly unlikely, further observa-
tional studies are needed to clarify the safety of radioio-
dine. Such studies will require thoughtful designs to
avoid the usual traps of non-randomised data such as
confounding by indication, lack of appropriate compara-
tive groups, and bias from uneven treatment time expo-
sures. Lastly, long-term quality of life studies will be
essential to understand the impact of therapy on lifelong
well-being.
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